Cipla [CIPLA] vs NGL Fine-Chem [NGLFINE] Detailed Stock Comparison
Cipla
NSE
Loading...
NGL Fine-Chem
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cipla wins in 16 metrics, NGL Fine-Chem wins in 4 metrics, with 0 ties. Cipla appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cipla | NGL Fine-Chem | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 23.23 | 41.10 | Cipla |
| Price-to-Book Ratio | 4.01 | 3.07 | NGL Fine-Chem |
| Debt-to-Equity Ratio | 1.40 | 27.30 | Cipla |
| PEG Ratio | 2.27 | 153.30 | Cipla |
| EV/EBITDA | 16.22 | 26.07 | Cipla |
| Profit Margin (TTM) | 19.62% | 5.54% | Cipla |
| Operating Margin (TTM) | 22.31% | 6.44% | Cipla |
| EBITDA Margin (TTM) | 22.31% | 6.44% | Cipla |
| Return on Equity | 16.85% | 7.48% | Cipla |
| Return on Assets (TTM) | 14.10% | 4.87% | Cipla |
| Free Cash Flow (TTM) | $34.57B | $-949.49M | Cipla |
| Dividend Yield | 1.72% | 0.26% | Cipla |
| 1-Year Return | 10.65% | -36.98% | Cipla |
| Price-to-Sales Ratio (TTM) | 4.55 | 2.27 | NGL Fine-Chem |
| Enterprise Value | $1,150.31B | $8.94B | Cipla |
| EV/Revenue Ratio | 4.19 | 2.34 | NGL Fine-Chem |
| Gross Profit Margin (TTM) | 68.25% | 50.19% | Cipla |
| Revenue per Share (TTM) | $340 | $618 | NGL Fine-Chem |
| Earnings per Share (Diluted) | $66.68 | $34.17 | Cipla |
| Beta (Stock Volatility) | 0.10 | 0.51 | Cipla |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cipla vs NGL Fine-Chem Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cipla | -0.03% | 1.84% | 8.07% | 7.45% | 7.93% | 7.67% |
| NGL Fine-Chem | -0.99% | 3.50% | 8.70% | 10.56% | 31.07% | -21.13% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cipla | 10.65% | 56.03% | 112.77% | 141.39% | 425.85% | 1,037.88% |
| NGL Fine-Chem | -36.98% | -11.75% | -23.95% | -23.95% | -23.95% | -23.95% |
Performance & Financial Health Analysis: Cipla vs NGL Fine-Chem
| Metric | CIPLA | NGLFINE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.25T | ₹8.68B |
| Market Cap Category | Large cap | Small cap |
| 10 Day Avg. Volume | 1,400,322 | 3,181 |
| 90 Day Avg. Volume | 1,666,300 | 2,917 |
| Last Close | ₹1,592.40 | ₹1,407.20 |
| 52 Week Range | ₹1,335.00 - ₹1,601.00 | ₹957.00 - ₹2,374.00 |
| % from 52W High | -0.54% | -40.72% |
| All-Time High | ₹1,601.00 (Aug 22, 2025) | ₹2,823.90 (Apr 22, 2024) |
| % from All-Time High | -0.54% | -50.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.15% |
| Quarterly Earnings Growth | 0.10% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.06% |
| Operating Margin (TTM) | 0.22% | 0.06% |
| Return on Equity (TTM) | 0.17% | 0.07% |
| Debt to Equity (MRQ) | 1.40 | 27.30 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹386.24 | ₹457.16 |
| Cash per Share (MRQ) | ₹131.44 | ₹106.07 |
| Operating Cash Flow (TTM) | ₹55.16B | ₹206.13M |
| Levered Free Cash Flow (TTM) | ₹52.73B | ₹211.24M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.72% | 0.26% |
| Last 12-Month Dividend | ₹26.00 | ₹3.50 |
Valuation & Enterprise Metrics Analysis: Cipla vs NGL Fine-Chem
| Metric | CIPLA | NGLFINE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 23.23 | 41.10 |
| Forward P/E | 24.38 | N/A |
| PEG Ratio | 2.27 | 153.30 |
| Price to Sales (TTM) | 4.55 | 2.27 |
| Price to Book (MRQ) | 4.01 | 3.07 |
| Market Capitalization | ||
| Market Capitalization | ₹1.25T | ₹8.68B |
| Enterprise Value | ₹1.15T | ₹8.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.19 | 2.34 |
| Enterprise to EBITDA | 16.22 | 26.07 |
| Risk & Other Metrics | ||
| Beta | 0.10 | 0.51 |
| Book Value per Share (MRQ) | ₹386.24 | ₹457.16 |
Financial Statements Comparison: Cipla vs NGL Fine-Chem
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CIPLA | NGLFINE |
|---|---|---|
| Revenue/Sales | ₹68.37B | ₹1.04B |
| Cost of Goods Sold | ₹21.71B | ₹518.92M |
| Gross Profit | ₹46.66B | ₹522.94M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹15.25B | ₹67.08M |
| EBITDA | ₹20.37B | ₹173.28M |
| Pre-Tax Income | ₹17.70B | ₹118.40M |
| Income Tax | ₹4.78B | ₹25.99M |
| Net Income (Profit) | ₹12.92B | ₹92.41M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CIPLA | NGLFINE |
|---|---|---|
| Cash & Equivalents | ₹5.89B | ₹5.83M |
| Total Current Assets | ₹232.89B | ₹2.35B |
| Total Current Liabilities | ₹54.84B | ₹1.19B |
| Long-Term Debt | ₹2.52B | ₹253.36M |
| Total Shareholders Equity | ₹312.89B | ₹2.82B |
| Retained Earnings | ₹256.44B | ₹2.77B |
| Property, Plant & Equipment | ₹52.62B | ₹1.42B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CIPLA | NGLFINE |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CIPLA | NGLFINE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,400,322 | 3,181 |
| Average Daily Volume (90 Day) | 1,666,300 | 2,917 |
| Shares Outstanding | 807.62M | 6.18M |
| Float Shares | 562.88M | 1.52M |
| % Held by Insiders | 0.31% | 0.74% |
| % Held by Institutions | 0.39% | 0.00% |
Dividend Analysis & Yield Comparison: Cipla vs NGL Fine-Chem
| Metric | CIPLA | NGLFINE |
|---|---|---|
| Last 12-Month Dividend | ₹26.00 | ₹3.50 |
| Last 12-Month Dividend Yield | 1.72% | 0.26% |
| 3-Year Avg Annual Dividend | ₹16.00 | ₹2.33 |
| 3-Year Avg Dividend Yield | 0.76% | 0.10% |
| 3-Year Total Dividends | ₹48.00 | ₹7.00 |
| Ex-Dividend Date | Jun 27, 2025 | Aug 12, 2025 |